Koss Olinger Consulting LLC Invests $649,000 in DaVita Inc. (NYSE:DVA)

Key Points

• Koss Olinger Consulting LLC invested approximately $649,000 in DaVita Inc., acquiring 4,240 shares during the first quarter as reported in their recent 13F filing.
• DaVita reported $2.95 EPS for the last quarter, exceeding analysts' expectations, with revenue growing 6.1% year-over-year to reach $3.38 billion.
• Analyst ratings on DaVita vary, with Barclays reducing the price target to $160.00, while Wall Street Zen upgraded the stock from a "hold" to a "buy" rating.

Koss Olinger Consulting LLC bought a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,240 shares of the company's stock, valued at approximately $649,000.

Several other hedge funds also recently made changes to their positions in the business. Measured Wealth Private Client Group LLC grew its stake in shares of DaVita by 29.4% during the first quarter. Measured Wealth Private Client Group LLC now owns 3,221 shares of the company's stock worth $493,000 after buying an additional 732 shares during the last quarter. National Bank of Canada FI grew its stake in shares of DaVita by 30.8% during the first quarter. National Bank of Canada FI now owns 53,791 shares of the company's stock worth $8,230,000 after buying an additional 12,666 shares during the last quarter. Y.D. More Investments Ltd bought a new stake in shares of DaVita during the first quarter worth $35,000. Arjuna Capital bought a new stake in shares of DaVita during the first quarter worth $1,269,000. Finally, ASR Vermogensbeheer N.V. bought a new stake in shares of DaVita during the first quarter worth $2,534,000. 90.12% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on DVA shares. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Truist Financial set a $148.00 price target on shares of DaVita in a report on Friday. Finally, Barclays cut their price target on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th.

Insider Transactions at DaVita

In other news, insider James O. Hearty sold 2,351 shares of the stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the transaction, the insider owned 26,038 shares of the company's stock, valued at $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is owned by corporate insiders.

DaVita Stock Performance

DVA traded up $3.03 during midday trading on Tuesday, reaching $132.08. The company had a trading volume of 755,764 shares, compared to its average volume of 917,332. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.34 and a current ratio of 1.39. The stock has a market cap of $9.44 billion, a PE ratio of 12.99, a P/E/G ratio of 0.92 and a beta of 1.09. DaVita Inc. has a 12-month low of $126.07 and a 12-month high of $179.60. The business has a 50-day moving average price of $139.84 and a two-hundred day moving average price of $146.10.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $2.95 earnings per share for the quarter, beating analysts' consensus estimates of $2.70 by $0.25. The firm had revenue of $3.38 billion for the quarter, compared to analysts' expectations of $3.36 billion. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The company's quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.00 earnings per share. On average, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.